Japanese guidance for use of biologics for psoriasis (the 2013 version)-Reference-Cited by-同舟云学术

Japanese guidance for use of biologics for psoriasis (the 2013 version)

Published:2013-09 Issue:9 Volume:40 Page:683-695
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

Ohtsuki Mamitaro¹,Terui Tadashi²,Ozawa Akira³,Morita Akimichi⁴,Sano Shigetoshi⁵,Takahashi Hidetoshi⁶,Komine Mayumi¹,Etoh Takafumi⁷,Igarashi Atsuyuki⁸,Torii Hideshi⁹,Asahina Akihiko¹⁰,Nemoto Osamu¹¹,Nakagawa Hidemi¹²,

Affiliation:

1. Department of Dermatology; Jichi Medical University, Shimotsuke

2. Department of Dermatology; Nihon University School of Medicine, Tokyo

3. Department of Dermatology; Tokai University School of Medicine, Isehara

4. Department of Geriatric and Environmental Dermatology; Nagoya City University Graduate School of Medical Science, Nagoya

5. Department of Dermatology; Kochi Medical School; Kochi University, Kochi

6. Department of Dermatology; Asahikawa Medical College, Asahikawa

7. Division of Dermatology; Tokyo Postal Services Agency Hospital, Tokyo

8. Division of Dermatology; NTT Medical Center Tokyo, Tokyo

9. Division of Dermatology; Social Health Insurance Medical Center, Tokyo

10. Department of Dermatology; National Hospital Organization; Sagamihara National Hospital, Sagamihara

11. Kojinkai Sapporo Skin Clinic, Sapporo

12. Department of Dermatology; The Jikei University School of Medicine, Tokyo; Japan

Publisher

Wiley

Subject

Dermatology,General Medicine

Reference17 articles.

1. Guideline and safety manual for use of biologic agents in psoriasis (the 2011 version);Ohtsuki;Jpn J Dermatol,2011

2. The guideline and safety manual for use of anti-TNFα agents in psoriasis;Ohtsuki;Jpn J Dermatol,2010

3. http://www.dermatol.or.jp/

4. The guidelines for diagnosis and treatment of generalized pustular psoriasis 2010 (Treatment guidelines incorporating TNFα inhibitors);Iwatsuki;Jpn J Dermatol,2010

5. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase 2/3 randomized controlled study;Asahina;J Dermatol,2010

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version);The Journal of Dermatology;2022-12-29

2. Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis;The Journal of Dermatology;2022-07-07

3. Comparison of Treatment Goals between Users of Biological and Non-Biological Therapies for Treatment of Psoriasis in Japan;Journal of Clinical Medicine;2021-12-07

4. Treatment practices and costs among patients with psoriatic arthritis: A Japanese hospital claims database analysis;Modern Rheumatology;2021-11-02

5. Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study;Dermatology and Therapy;2021-02-19